Scarica l'app Stockscreener
1.53
4.97%
-0.08
Dopo l'orario di chiusura:
1.53
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Century Therapeutics appoints Truitt. Century Therapeutics stock has USD 309.6 million value. - AD HOC NEWS
Century Therapeutics rated speculative Buy on p... - Pluang
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet (NASDAQ:IPSC) - Seeking Alpha
Century Therapeutics (IPSC) Slips 1.50% to $1.65, Testing Support Near $1.57Triple MA Cross - siam.in
Form 144 Century Therapeutics For: 25 September By Investing.com - Investing.com Canada
Century Therapeutics stock falls 6.88 percent as milestones approach - AD HOC NEWS
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to S&P Global BMI Index - marketscreener.com
Century Therapeutics stock extends strong run as IPSC jumps over 700 percent in 12 months - AD HOC NEWS
Century Therapeutics stock falls as IPSC trades near 52-week low - AD HOC NEWS
Russotti Gregory Disposes 2,587 Shares of Century Therapeutics (NASDAQ: IPSC) at $1.93 Each - kalkinemedia.com
Century Therapeutics SVP Douglas Carr sells $3,199 in shares By Investing.com - Investing.com South Africa
Century Therapeutics SVP Douglas Carr sells $3,199 in shares - Investing.com
Century Therapeutics (IPSC) exec sale covers RSU taxes - Stock Titan
Century Therapeutics (IPSC) CEO holds 3,633,839 shares after tax move - Stock Titan
Century Therapeutics (NASDAQ: IPSC) officer intends $4,994 sale of stock - Stock Titan
Century Therapeutics (NASDAQ: IPSC) officer lines up 1,658-share stock sale - Stock Titan
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Century Therapeutics (IPSC) awards 148,000 options vesting over 3 years - Stock Titan
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline - The Globe and Mail
Century Therapeutics' SVP Finance Carr Douglas Sells 254 Shares at $2.05 Each (NASDAQ: IPSC) - kalkinemedia.com
Century Therapeutics (NASDAQ: IPSC) Insider Russotti Gregory Sells 534 Shares, Retains 511,785 Shares - Kalkine Media
Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.com - Investing.com Australia
Century Therapeutics appoints iECURE CEO Joseph Truitt to board - Bitget
Century Therapeutics Adds Joseph Truitt to Board of Directors - Minichart
Century Therapeutics CEO Brent Pfeiffenberger Withholds Shares for Tax on RSU Vesting - Kalkine Media
Century Therapeutics CTO Gregory Russotti Executes Automatic Sale of 534 Shares for Tax Withholding - kalkinemedia.com
Century Therapeutics appoints Joseph Truitt to board By Investing.com - Investing.com Nigeria
Century Therapeutics SVP sells $520 in stock for tax withholding - Investing.com
Century Therapeutics (IPSC) CEO shares withheld for taxes on RSU vesting - Stock Titan
Tax-withholding sale trims Century Therapeutics (NASDAQ: IPSC) insider by 534 shares - Stock Titan
Automatic tax sale leaves Century Therapeutics (NASDAQ: IPSC) SVP with 504,565 shares - Stock Titan
Century Therapeutics adds director, sets 2026 trial timelines - Stock Titan
Century Therapeutics appoints Joseph Truitt to board - Investing.com
Century Therapeutics Appoints Joseph Truitt to Board of Directors - Yahoo Finance UK
Century Therapeutics (NASDAQ: IPSC) officer plans stock sale partly to cover taxes - Stock Titan
Century (IPSC) Range: Rises 2.66% to $2.12 in the Latest Reading; Price Setup: the Supplied Trading Band Runs From $2.01 to $2.23 in the Latest SessionDynamic Hedging - careplusvn.com
Century (IPSC) Earnings Reading: EPS Beats Its Estimate at the Close; Share Move: The Stock Records a 4.27% Decrease in Latest TradingGuidance vs Actual - vinanet.vn
Century Targets FDA Filing for Diabetes Cell Therapy - MyChesCo
Century Therapeutics CEO Brent Pfeiffenberger Completes RSU Tax Withholding Share Transaction - Kalkine Media
Century Therapeutics (IPSC) CEO stock withheld for taxes - Stock Titan
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings - MarketBeat
IPSC Q1 2026 Earnings: Narrower-Than-Expected Loss Yields 31.76% EPS SurpriseMid-Term Outlook - vinanet.vn
TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating - Moomoo
Century Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Century Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results - MarketBeat
Century Therapeutics Announces Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Century Therapeutics Inc For: 12 August - Investing.com India
Century Therapeutics Reports Q2 Results, Pipeline Advancements - TipRanks
Form 8K Century Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):